The rapid diagnostic test for kala-azar is the rK39 immunochromatographic rapid test, which detects anti-Leishmania donovani complex antibodies to the recombinant K39 antigen. It uses serum, plasma or whole blood and gives results in 10 to 20 minutes, suitable for field settings. Positive results support clinical diagnosis, but negative or uncertain cases may need confirmatory testing (DAT, PCR or bone marrow examination).

The rK39 rapid diagnostic test is a point‑of‑care lateral‑flow assay that detects antibodies to the recombinant K39 antigen of Leishmania species causing visceral leishmaniasis. Performed on serum, plasma or finger‑prick blood, it yields results in 10–20 minutes. It supports kala‑azar diagnosis, though sensitivity and specificity vary by region; results should be interpreted with clinical findings and other tests.

The test for Leishmania antibodies is serological testing on blood/serum—commonly the rK39 rapid diagnostic test, direct agglutination test (DAT), or ELISA. rK39 RDTs are widely used and sensitive for visceral leishmaniasis; serology is less reliable for cutaneous forms. Positive serology often needs confirmation by parasitological methods (microscopy, culture) or PCR.

The common blood test for kala-azar (visceral leishmaniasis) is the rK39 rapid immunochromatographic test, which detects anti‑Leishmania antibodies. It’s a point‑of‑care serologic test with high sensitivity in many settings, often used to diagnose symptomatic patients. Other options include the direct agglutination test (DAT), PCR for parasite DNA in blood, and confirmatory parasitological detection from splenic or bone‑marrow aspirates.

A rapid diagnostic test usually involves collecting a sample (throat/nasal swab, finger-prick blood, or urine), placing it into a buffer or onto a test strip, then waiting the manufacturer-specified time (often 10 to 30 minutes). A visible line, color change, or digital readout shows the result; a control line must appear for validity. Follow instructions and get laboratory confirmation if results are positive or unclear.

Rapid diagnostic tests for sickle cell disease include point-of-care lateral-flow immunoassays (e.g., Sickle SCAN, HemoTypeSC) and quick solubility tests. These POC assays detect haemoglobin variants (HbS, HbC) in minutes and are used for screening. A rapid solubility test indicates presence of sickling haemoglobin but cannot reliably distinguish trait from disease; positives should be confirmed by HPLC or hemoglobin electrophoresis.